Filter Results:
(705)
Show Results For
- All HBS Web
(705)
- News (190)
- Research (468)
- Events (1)
- Multimedia (24)
- Faculty Publications (440)
Show Results For
- All HBS Web
(705)
- News (190)
- Research (468)
- Events (1)
- Multimedia (24)
- Faculty Publications (440)
- Article
Ten Year Sunset Rule for Healthcare Regulation Is a Nonstarter and Discouragement to Post-COVID-19 Investment
By: Regina E. Herzlinger and Eugene Schneller
U.S. healthcare delivery has not benefitted from the same productivity growth as many other service industries, such as bricks and mortar retailing, a loss that has gravely diminished cost control and access. Regulatory capture, which creates barriers to venture... View Details
Keywords: Health Care; COVID-19; Regulation; Health Care and Treatment; Health Pandemics; Governing Rules, Regulations, and Reforms; Investment
Herzlinger, Regina E., and Eugene Schneller. "Ten Year Sunset Rule for Healthcare Regulation Is a Nonstarter and Discouragement to Post-COVID-19 Investment." Journal of Health Care Finance 47, no. 4 (Spring 2021). (Special Commentary.)
- 8 Sep 2020
- Interview
The U.S. Health Care System: From Dysfunction to Functioning
By: Regina E. Herzlinger and Edward Shin
Herzlinger, Regina E., and Edward Shin. "The U.S. Health Care System: From Dysfunction to Functioning." Q-Reviews (podcast), Quality Reviews, Inc., September 8, 2020.
- February 2018
- Case
Health Savings Accounts: Enabling Consumer Participation
By: Regina E. Herzlinger and James Wallace
Health savings accounts (HSAs), a creation of the 2003 Medicare Modernization Act, had become an integral part of the drive toward consumer-driven health care. Coupled with high-deductible health plans, HSAs allowed consumers to directly control a significant part of... View Details
- March 2015 (Revised February 2022)
- Supplement
CV Ingenuity (B): Epilogue
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen used a lea-nfunding, iconoclastic strategy for his start up for a drug eluding balloon for peripheral artery disease. His giant competitors were first movers. Did Duke obtain the funding he sought? How did his DEB fare versus that of his competitors?
The... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Strategy; Health Industry; Medical Devices and Supplies Industry; United States; Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (B): Epilogue." Harvard Business School Supplement 315-087, March 2015. (Revised February 2022.)
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Health Industry; Medical Devices and Supplies Industry; United States; Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies." Harvard Business School Case 315-045, March 2015. (Revised January 2024.)
- April 1995 (Revised August 1995)
- Supplement
Empire Blue Cross and Blue Shield (D)
By: Regina E. Herzlinger and Ramona Hilgenkamp
Supplements the (A) case. View Details
Herzlinger, Regina E., and Ramona Hilgenkamp. "Empire Blue Cross and Blue Shield (D)." Harvard Business School Supplement 195-219, April 1995. (Revised August 1995.)
- April 1995 (Revised December 2006)
- Case
Identify the Nonprofit
By: Regina E. Herzlinger and Ramona Hilgenkamp
This case presents financial statements and selected ratios for seven unidentified nonprofit organizations and asks that each set of financial information be matched with one of the following nonprofit entities: a public television station, a suburban hospital, a... View Details
Herzlinger, Regina E., and Ramona Hilgenkamp. "Identify the Nonprofit." Harvard Business School Case 195-215, April 1995. (Revised December 2006.)
- February 1995
- Background Note
Health Information Industry Note
By: Regina E. Herzlinger and VJ Pappas
Herzlinger, Regina E., and VJ Pappas. "Health Information Industry Note." Harvard Business School Background Note 195-206, February 1995.
- May 2014
- Case
Health Care Accountability: Examples in Cancer Treatment
By: Regina E. Herzlinger and Natalie Kindred
This case is designed to support a discussion of the importance of outcomes evidence in empowering the public to make better health care decisions, the desired level of transparency and accountability for health care providers, and the issues with current measuring and... View Details
Keywords: Accountability; Health Care; Cancer; Cancer Treatment; Memorial Sloan Kettering Cancer Center; Cancer Treatment Centers Of America; Vantage Oncology; Radiology; Risk Adjustment; Treatment Outcomes; Health Care Outcomes; Prostate Cancer; Transparency; Health Care and Treatment; Risk Management; Outcome or Result; Health Industry; United States
- March 2014 (Revised September 2014)
- Supplement
Cancer Treatment Centers of America® (B)
By: Regina E. Herzlinger and Natalie Kindred
This case, a follow-up to Cancer Treatment Centers of America (A), HBS No. 313-012, begins with the debate over New Hampshire's certificate-of-need (CON) law, which restricts hospital expansion. This debate ignited significant public criticism of Cancer Treatment... View Details
Keywords: Cancer; Cancer Treatment; Accountability; Outcomes; Outcomes Reporting; Outcomes Measurement; Survival; For-profit Hospitals; Health Care; Healthcare; Hospital; Certificate Of Need; Health Care and Treatment; Outcome or Result; Corporate Accountability; Policy; Health Industry; United States
Herzlinger, Regina E., and Natalie Kindred. "Cancer Treatment Centers of America® (B)." Harvard Business School Supplement 314-003, March 2014. (Revised September 2014.)
- August 2013 (Revised August 2014)
- Technical Note
Population Health Management—Techniques and Tools
By: Regina E. Herzlinger and Kyle Bertke
Companion note to "Amil and the Health Care System in Brazil," Harvard Business School Case No. 312-029, January 2014 View Details
- March 2010
- Supplement
Boston Scientific Corporation (B)
By: Regina E. Herzlinger and Charlie Attlan
The case provides the denoument for Boston Scientific Corporation (A) HBS No. 310079. View Details
Keywords: Medical Devices and Supplies Industry
- March 2008 (Revised January 2010)
- Background Note
Note on Accountability in the U.S. Health Care System
By: Regina E. Herzlinger and Michael Millenson
This note explains how health care providers, health insurers, and consumers are held accountable for their performance and the entrepreneurial opportunities thus created. View Details
Keywords: Entrepreneurship; Ethics; Insurance; Corporate Accountability; Health Care and Treatment; Demand and Consumers; Health Industry; United States
Herzlinger, Regina E., and Michael Millenson. "Note on Accountability in the U.S. Health Care System." Harvard Business School Background Note 308-111, March 2008. (Revised January 2010.)
- February 2008 (Revised August 2012)
- Background Note
Note on Medical Travel
By: Regina E. Herzlinger and Sara Green
Background notes for MedVal and Fortis case studies. View Details
Keywords: Cost; Health Care and Treatment; Cross-Cultural and Cross-Border Issues; Health Industry; Tourism Industry; India
Herzlinger, Regina E., and Sara Green. "Note on Medical Travel." Harvard Business School Background Note 308-084, February 2008. (Revised August 2012.)
- June 2005 (Revised August 2006)
- Exercise
New Sector Alliance (B)
By: Regina E. Herzlinger and Louisa Neissa
Supplements the (A) case. View Details
Herzlinger, Regina E., and Louisa Neissa. "New Sector Alliance (B)." Harvard Business School Exercise 305-091, June 2005. (Revised August 2006.)
- June 2003 (Revised March 2008)
- Case
Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene
By: Regina E. Herzlinger and Marc Aquino
Personalized medicine requires the identification of mutated genes. Schering-Plough's search for the one related to asthma requires finding families with the disease. Examines the industry that helps conduct such research, including contract research organizations. View Details
Keywords: Health Disorders; Research and Development; Genetics; Biotechnology Industry; Pharmaceutical Industry
Herzlinger, Regina E., and Marc Aquino. "Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene." Harvard Business School Case 303-044, June 2003. (Revised March 2008.)
- September 2002 (Revised January 2013)
- Case
MedCath Corporation (A)
By: Regina E. Herzlinger and Pete Stavros
MedCath is a horizontally integrated chain of heart hospitals that partners with local cardiologists. It claims that its focus leads to better and cheaper results than those of an everything-for-everybody general hospital. Community hospitals generally vehemently... View Details
Keywords: Medical Specialties; Market Entry and Exit; Service Delivery; Conflict and Resolution; Horizontal Integration; Health Industry
Herzlinger, Regina E., and Pete Stavros. "MedCath Corporation (A)." Harvard Business School Case 303-041, September 2002. (Revised January 2013.)
- August 2012 (Revised August 2012)
- Case
HealthAllies (A)
By: Regina E. Herzlinger and Michael Sherman
This case describes a "do good and do well" firm that enables individuals to buy health care services at discounted prices. It delineates the characteristics of the uninsured and others who are the primary targets for the firm. "HealthAllies (B)" provides information... View Details
Keywords: Entrepreneurship; Health Care and Treatment; Marketing Channels; Demand and Consumers; Commercialization; Health Industry
Herzlinger, Regina E., and Michael Sherman. "HealthAllies (A)." Harvard Business School Case 302-019, August 2012. (Revised from original August 2001 version.)
- January 2023
- Teaching Note
Identify the Health Care Venture
By: Regina E. Herzlinger and James Wallace
Teaching Note for HBS Exercise No. 323-061. View Details
- Forthcoming
- Article
From Bupkis to Sechel in Health Care
By: Regina E. Herzlinger and Richard Boxer
Fifty years ago, famed economist Milton Friedman declared that “The social responsibility of business is to increase its profits.” This free market manifesto was adopted by the healthcare industry as well. But transactional has evolved into transformational with the... View Details
Keywords: Corporate Accountability; Customer Focus and Relationships; Corporate Social Responsibility and Impact; Health Industry
Herzlinger, Regina E., and Richard Boxer. "From Bupkis to Sechel in Health Care." JAMA, the Journal of the American Medical Association (forthcoming).